To be able to use the full range of Shopware 6, we recommend activating Javascript in your browser.

Infectious disease

EBV EBNA-1 Peptide Pool

Product number: LB01674

€301.30*

Prices excl. VAT plus shipping costs

Available, delivery time: 1-3 days

sterile and endotoxin free

Delivery Format: The product is supplied freeze dried.

Caution: For research use only. Not for use in humans.

1

Add to Cart

Description

Peptide pool of 158 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 1 (EBNA1) (Uniprot ID: P03211) of Epstein-Barr virus (HHV4) for T cell assays.

One unit allows the stimulation of 2,5 x 10⁸ cells.

TechData

Gene:	EBNA1
Delivery:	1-3 days
Counterion:	TFA
Length:	641 amino acids
No. Peptides:	158 peptides
Amount/Aliquote:	15 nmol (approx. 25µg)/peptide for stimulation of 2,5 x 108 cells
Solubility:	Dissolve in a minimum amount of pure DMSO (40µl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system.
Protein:	Epstein-Barr nuclear antigen 1
UniProt Id:	P03211
Species:	Epstein-Barr virus (EBV; Human herpesvirus 4)
Application:	T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication:	Infectious disease, Cancer, Neuroscience

Documents

Storage and handling of peptides

Probing of membranes with HRP

References

Milanesi, Samantha et al. “Variants in human CD48 lead to impaired T cell immunity and increased inflammation.” The Journal of clinical investigation vol. 136,11 e191340. 14 Apr. 2026, doi:10.1172/JCI191340

More EBNA peptides

EBNA 3a (596-604)

EBNA 3a (596-604)

This peptide represents an HLA-A2-restricted epitope of the Epstein-Barr virus nuclear antigen 3 (EBNA 3). EBNA 3 is a transcriptional regulatory protein that promotes B cell activation through the RBP-Jk pathway. This peptide is used in the study of immunotherapy for solid organ transplant patients.

From €105.00*

EBNA-1 Protein (562-570)

EBNA-1 Protein (562-570)

The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalo virus). On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions.

From €105.00*

EBV (EBNA-3a) Peptide Pool

EBV (EBNA-3a) Peptide Pool

The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays. Scientific Background EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma. During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation: EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency. EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs. EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression. These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

€301.30*

EBV (EBNA-3b) Peptide Pool

EBV (EBNA-3b) Peptide Pool

Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€301.30*

EBV EBNA 3A 246-253 (HLA-A*24:02)

EBV EBNA 3A 246-253 (HLA-A*24:02)

RYSIFFDY is a linear peptidic epitope (epitope ID 56650) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays

From €105.00*

EBV EBNA 3B 399-408 (HLA-A*11:01)

EBV EBNA 3B 399-408 (HLA-A*11:01)

Antigen Peptide EBV EBNA3B 399-408 (HLA-A*11:01) AVFDRKSDAK for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*

EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04)

EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04)

RRIYDLIEL is a linear peptidic epitope (epitope ID55620) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-1 407-417 (HLA-B*35:01)

EBV EBNA-1 407-417 (HLA-B*35:01)

Antigen Peptide EBV EBNA-1 407-417 (HLA-B*35:01) HPVGEADYFEY for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. HPVGEADYFEY for stimulation of human EBV EBNA-1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*3501 allele. HPVGEADYFEY is a linear peptidic epitope (epitope ID24536) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €105.00*

EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A

EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A

EBNA1-derived peptide of HPVAEADYFEY covering 407-417 and B*35:08 molecule. HPVAEADYFEY is a linear peptidic epitope (epitope ID 227777) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €106.60*

EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D

EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D

EBV EBNA1-derived peptide of HPVGDADYFEY covering 407-417 and B*35:08 molecule. HPVGDADYFEY is a linear peptidic epitope (epitope ID 24525) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €106.60*

EBV EBNA-1 72-80 (HLA-B*35:01)

EBV EBNA-1 72-80 (HLA-B*35:01)

RPQKRPSCI is a linear peptidic epitope studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays.

From €105.00*

EBV EBNA-2 Peptide Pool

EBV EBNA-2 Peptide Pool

The EBV EBNA-2 Peptide Pool from peptides&elephants is designed for reliable stimulation and detection of EBV-specific T-cell responses in immunological research. The pool consists of 119 overlapping peptides (15-mers with an 11-amino-acid overlap) spanning Epstein–Barr nuclear antigen 2 (EBNA2) from Epstein–Barr virus strain B95-8 (UniProt ID: P12978). The Epstein-Barr virus is also known as Human herpesvirus 4 (HHV-4). EBNA2 is one of the earliest viral proteins expressed after infection of B cells and acts as a central transcriptional regulator that reprograms host and viral gene expression. Through interactions with numerous sites in the host genome, EBNA2 cooperates with EBNA-LP to activate key cellular pathways, including transient activation of the MYC proto-oncogene, which drives early B-cell proliferation and supports survival during the establishment of EBV latency. EBNA2 activity also contributes to the transition from the initial Wp promoter–driven transcription toward the Cp promoter–controlled latency program IIb, in which multiple EBV nuclear antigens are expressed from a polycistronic transcript. This shift allows the virus to balance rapid proliferation with controlled persistence. Learn more about EBNA2-mediated transcriptional reprogramming and MYC regulation during early EBV infection in the Peptide Insights section of peptides&elephants. Applications Suitable for multiple T-cell–based assays, including: ELISpot assays Intracellular cytokine staining (ICS) FluoroSpot assays T-cell proliferation assays Immune monitoring in EBV research Capacity One unit allows the stimulation of 2.5 × 10⁸ cells. The EBV EBNA-2 Peptide Pool provides a comprehensive tool for studying EBV-specific immune responses, latency establishment, and virus-host interactions in basic and translational research.

€277.50*

EBV EBNA-3A 325-333 (HLA-B*08:01)

EBV EBNA-3A 325-333 (HLA-B*08:01)

Antigen Peptide EBV EBNA3A HLA-B*08:01 (FLRGRAYGL) for stimulation of human EBV EBNA-3A(325-333) -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0801 allele.

From €105.00*

EBV EBNA-3A 379-387 (HLA-B*07:02)

EBV EBNA-3A 379-387 (HLA-B*07:02)

Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

From €105.00*

EBV EBNA-3A 458-466 (HLA-B*35:01)

EBV EBNA-3A 458-466 (HLA-B*35:01)

HLA-B35-restricted epitope from Epstein-Barr Virus latent nuclear antigen 3A (458-466) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*

EBV EBNA-3A 603-611 (HLA-A*03:01)

EBV EBNA-3A 603-611 (HLA-A*03:01)

RLRAEAQVK is a linear peptidic epitope (epitope ID54728) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-3C 284-293 (HLA-A*02:01)

EBV EBNA-3C 284-293 (HLA-A*02:01)

LLDFVRFMGV is a linear peptidic epitope (epitope ID 37153) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus) and Other Human herpesvirus 4 (Epstein Barr virus) protein from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-3C 881-889 (HLA-B*07:02)

EBV EBNA-3C 881-889 (HLA-B*07:02)

QPRAPIRPI is a linear peptidic epitope (epitope ID 51946) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA2 280-290 (DRB1*01:01)

EBV EBNA2 280-290 (DRB1*01:01)

The peptide EBV EBNA2 280–290 (TVFYNIPPMPL) from peptides&elephants is a synthetic antigenic epitope derived from Epstein–Barr nuclear antigen 2 (EBNA2) of Epstein–Barr virus (Human herpesvirus 4). EBNA2 is a central transcriptional regulator expressed during early stages of EBV infection and plays a crucial role in the establishment of viral latency and the reprogramming of infected B cells.For a deeper understanding of the biological role of EBNA2 in early EBV infection and viral transcriptional control, explore the EBV Peptide Insights section by peptides&elephants. EBV EBNA2 280–290 corresponds to a linear T-cell epitope (IEDB ID 67007) located within the EBNA2 protein (UniProt ID: P12978). It has been experimentally studied for immune reactivity and evaluated in multiple functional T-cell assays. The epitope is presented in the context of HLA-DRB1*01:01, enabling recognition by CD4⁺ T cells. Experimental studies have demonstrated positive immune responses in several assay formats, including interferon-γ (IFNγ) release assays, T-cell proliferation assays, and cytotoxicity assays. These findings indicate that the peptide can effectively stimulate EBNA2-specific T-cell responses and is therefore suitable for applications in cellular immunology and EBV research. Because EBNA2 is a key driver of early transcriptional reprogramming in EBV-infected cells, peptides derived from this protein are valuable tools for studying virus-host interactions, T-cell immunity to EBV, and immune recognition of latency-associated antigens. Applications Stimulation of EBV-specific T cells ELISpot and FluoroSpot assays Intracellular cytokine staining (ICS) T-cell proliferation assays Cytotoxicity assays Epitope validation and immune monitoring in EBV research

From €109.20*

EBV EBNA3A 158-166 (HLA-B*08:01)

EBV EBNA3A 158-166 (HLA-B*08:01)

QAKWRLQTL is a linear peptidic epitope (epitope ID50298) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01)

EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01)

The peptide EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) with the amino acid sequence IVTDFSVIK is a linear peptidic epitope (epitope ID 29466) studied as part of Epstein-Barr nuclear antigen 4 (UniProt:P03203) from Human herpesvirus 4 (Epstein Barr virus).EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

From €105.00*

EBV EBNA3C 281-290 (HLA-B*44:05)

EBV EBNA3C 281-290 (HLA-B*44:05)

EBNA3C-derived peptide of EENLLDFVRF covering 281-290 and B*44:05 molecule. The EBV EBNA3C 281-290 (HLA-B*44:05) peptide recognizes CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. EENLLDFVRF is a linear peptidic epitope (epitope ID11804) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

More EBV Peptide Pools

EBV (BZLF1) Peptide Pool

EBV (BZLF1) Peptide Pool

Peptide pool of 59 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Trans-activator protein BZLF1 (UniProt ID: P03206) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€277.50*

EBV (EBNA-3a) Peptide Pool

EBV (EBNA-3a) Peptide Pool

The EBV (EBNA-3a) Peptide Pool from peptides&elephants is designed for in vitro T cell stimulation and epitope analysis in research on Epstein-Barr virus (EBV, HHV-4). This pool contains 234 synthetic 15-mer peptides, overlapping by 11 amino acids, and spans the complete sequence of EBNA-3a (Epstein-Barr nuclear antigen 3a; UniProt ID: P12977). Each unit enables the stimulation of up to 2.5 × 10⁸ peripheral blood mononuclear cells (PBMCs) and is ideal for use in ELISpot, intracellular cytokine staining (ICS), and flow cytometry-based T cell assays. Scientific Background EBV is a ubiquitous herpesvirus that infects more than 90% of the global population. It is the causative agent of infectious mononucleosis and is closely associated with several B cell malignancies, including post-transplant lymphoproliferative disease (PTLD), diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma, and Hodgkin lymphoma. During latency, EBV can enter different gene expression programs. Latency type III, in which all nine latent proteins are expressed, is the only form capable of transforming B cells in vitro, resulting in lymphoblastoid cell lines (LCLs). Among these latency proteins, EBNA-3a plays a supportive but non-essential role in B cell transformation: EBV mutants lacking EBNA-3a can still transform B cells, but with significantly reduced efficiency. EBNA-3a–deficient LCLs proliferate more slowly and show increased apoptosis compared to wild-type virus–derived LCLs. EBNA-3a appears to regulate a subset of cellular genes, some of which overlap with those regulated by EBNA2. The two proteins can act antagonistically or cooperatively to control gene expression. These findings position EBNA-3a as a key modulator of B cell proliferation and survival during EBV latency, and as a relevant CD8⁺ T cell target in both basic immunological studies and translational research.

€301.30*

EBV (EBNA-3b) Peptide Pool

EBV (EBNA-3b) Peptide Pool

Peptide pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€301.30*

EBV (GP350/GP340) Peptide Pool

EBV (GP350/GP340) Peptide Pool

Peptide pool of 224 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Envelope glycoprotein GP350/GP340 (UniProt ID: P03200) of Epstein-Barr virus (EBV, Humanes Herpesvirus 4, HHV4). One unit allows the stimulation of 2,5 x 108 cells. gp350/gp340 versus gp350/220 The EBV envelope glycoprotein gp350/gp340 (or gp350/220) is encoded by the BLLF1 gene and represents one of the most abundant surface proteins of the virion. The protein exists in multiple isoforms generated by alternative splicing. While gp350 denotes the full-length form, gp340 and gp220 refer to truncated isoforms of the same glycoprotein, which retain identical biological function. Differences in naming (gp340 vs. gp220) arise from historical nomenclature, experimental detection methods, and variations in glycosylation state. Initial attachment and endocytosis Gp350/gp340 belongs to the core set of EBV glycoproteins that define viral tropism and host cell interaction – together with gp42, BMRF2, gH/gL, and gB. Gp350/gp340 plays a central role in viral attachment and entry into B lymphocytes. Through molecular mimicry of complement components, gp350/gp340 specifically recognizes complement receptor 1 (CR1/CD35) and complement receptor 2 (CR2/CD21) on B cells. This interaction mediates the initial attachment of EBV particles and triggers endocytosis of the immobilized virion, marking the first step of EBV infection in B lymphocytes. Major target of immune responses Due to its surface exposure, high abundance, and essential role in viral entry, gp350/gp340 represents a major target of humoral and cellular immune responses. Peptides derived from gp350/gp340 are widely used to study EBV-specific T cell immunity, epitope recognition, and immune monitoring in the context of EBV infection, EBV-associated malignancies, and vaccine development. The EBV (gp350/gp340) Peptide Pool from peptides&elephants provides comprehensive sequence coverage of this key viral glycoprotein and is ideally suited for applications such as T cell stimulation assays, epitope mapping, and immunological profiling in EBV research.

€301.30*

EBV (LMP1) Peptide Pool

EBV (LMP1) Peptide Pool

Peptide pool of 94 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Latent membrane protein 1 (LMP1) (UniProt ID: P03230) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€333.20*

EBV (LMP2A) Peptide Pool

EBV (LMP2A) Peptide Pool

Peptide pool of 27 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Latent membrane protein 2A (LMP2A) (UniProt ID: A8CDV5) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

Tip

EBV BARF1 Peptide Pool

EBV BARF1 Peptide Pool

Peptide pool of 53 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Secreted protein BARF1 (UniProt: P03225) of Homo sapiens Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4). One unit allows the stimulation of 2,5 x 108 cells.

€277.50*

EBV control Peptide Pool (>95% HPLC)

EBV control Peptide Pool (>95% HPLC)

This peptide pool consists of 26 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Epstein-Barr virus (EBV). One unit allows the stimulation of 2,5 x 108 cells.

€237.50*

EBV EBNA-2 Peptide Pool

EBV EBNA-2 Peptide Pool

The EBV EBNA-2 Peptide Pool from peptides&elephants is designed for reliable stimulation and detection of EBV-specific T-cell responses in immunological research. The pool consists of 119 overlapping peptides (15-mers with an 11-amino-acid overlap) spanning Epstein–Barr nuclear antigen 2 (EBNA2) from Epstein–Barr virus strain B95-8 (UniProt ID: P12978). The Epstein-Barr virus is also known as Human herpesvirus 4 (HHV-4). EBNA2 is one of the earliest viral proteins expressed after infection of B cells and acts as a central transcriptional regulator that reprograms host and viral gene expression. Through interactions with numerous sites in the host genome, EBNA2 cooperates with EBNA-LP to activate key cellular pathways, including transient activation of the MYC proto-oncogene, which drives early B-cell proliferation and supports survival during the establishment of EBV latency. EBNA2 activity also contributes to the transition from the initial Wp promoter–driven transcription toward the Cp promoter–controlled latency program IIb, in which multiple EBV nuclear antigens are expressed from a polycistronic transcript. This shift allows the virus to balance rapid proliferation with controlled persistence. Learn more about EBNA2-mediated transcriptional reprogramming and MYC regulation during early EBV infection in the Peptide Insights section of peptides&elephants. Applications Suitable for multiple T-cell–based assays, including: ELISpot assays Intracellular cytokine staining (ICS) FluoroSpot assays T-cell proliferation assays Immune monitoring in EBV research Capacity One unit allows the stimulation of 2.5 × 10⁸ cells. The EBV EBNA-2 Peptide Pool provides a comprehensive tool for studying EBV-specific immune responses, latency establishment, and virus-host interactions in basic and translational research.

€277.50*

EBV EBNA Peptides

EBNA 3a (596-604)

EBNA 3a (596-604)

This peptide represents an HLA-A2-restricted epitope of the Epstein-Barr virus nuclear antigen 3 (EBNA 3). EBNA 3 is a transcriptional regulatory protein that promotes B cell activation through the RBP-Jk pathway. This peptide is used in the study of immunotherapy for solid organ transplant patients.

From €105.00*

EBNA-1 Protein (562-570)

EBNA-1 Protein (562-570)

The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalo virus). On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions.

From €105.00*

EBV EBNA 3A 246-253 (HLA-A*24:02)

EBV EBNA 3A 246-253 (HLA-A*24:02)

RYSIFFDY is a linear peptidic epitope (epitope ID 56650) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays

From €105.00*

EBV EBNA 3B 399-408 (HLA-A*11:01)

EBV EBNA 3B 399-408 (HLA-A*11:01)

Antigen Peptide EBV EBNA3B 399-408 (HLA-A*11:01) AVFDRKSDAK for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*

EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04)

EBV EBNA 3C 258-266 (HLA-B*27:02)(HLA-B*27:05)(HLA-B*27:04)

RRIYDLIEL is a linear peptidic epitope (epitope ID55620) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-1 407-417 (HLA-B*35:01)

EBV EBNA-1 407-417 (HLA-B*35:01)

Antigen Peptide EBV EBNA-1 407-417 (HLA-B*35:01) HPVGEADYFEY for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. HPVGEADYFEY for stimulation of human EBV EBNA-1-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*3501 allele. HPVGEADYFEY is a linear peptidic epitope (epitope ID24536) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €105.00*

EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A

EBV EBNA-1 407-417 mutant (HLA-B*35:01) 410A

EBNA1-derived peptide of HPVAEADYFEY covering 407-417 and B*35:08 molecule. HPVAEADYFEY is a linear peptidic epitope (epitope ID 227777) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays.

From €106.60*

EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D

EBV EBNA-1 407-417 mutant (HLA-B*35:08) 411D

EBV EBNA1-derived peptide of HPVGDADYFEY covering 407-417 and B*35:08 molecule. HPVGDADYFEY is a linear peptidic epitope (epitope ID 24525) studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €106.60*

EBV EBNA-1 72-80 (HLA-B*35:01)

EBV EBNA-1 72-80 (HLA-B*35:01)

RPQKRPSCI is a linear peptidic epitope studied as part of Epstein-Barr nuclear antigen 1 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays.

From €105.00*

EBV EBNA-3A 325-333 (HLA-B*08:01)

EBV EBNA-3A 325-333 (HLA-B*08:01)

Antigen Peptide EBV EBNA3A HLA-B*08:01 (FLRGRAYGL) for stimulation of human EBV EBNA-3A(325-333) -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0801 allele.

From €105.00*

EBV EBNA-3A 379-387 (HLA-B*07:02)

EBV EBNA-3A 379-387 (HLA-B*07:02)

Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

From €105.00*

EBV EBNA-3A 458-466 (HLA-B*35:01)

EBV EBNA-3A 458-466 (HLA-B*35:01)

HLA-B35-restricted epitope from Epstein-Barr Virus latent nuclear antigen 3A (458-466) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*

EBV EBNA-3A 603-611 (HLA-A*03:01)

EBV EBNA-3A 603-611 (HLA-A*03:01)

RLRAEAQVK is a linear peptidic epitope (epitope ID54728) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-3C 284-293 (HLA-A*02:01)

EBV EBNA-3C 284-293 (HLA-A*02:01)

LLDFVRFMGV is a linear peptidic epitope (epitope ID 37153) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus) and Other Human herpesvirus 4 (Epstein Barr virus) protein from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA-3C 881-889 (HLA-B*07:02)

EBV EBNA-3C 881-889 (HLA-B*07:02)

QPRAPIRPI is a linear peptidic epitope (epitope ID 51946) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA2 280-290 (DRB1*01:01)

EBV EBNA2 280-290 (DRB1*01:01)

The peptide EBV EBNA2 280–290 (TVFYNIPPMPL) from peptides&elephants is a synthetic antigenic epitope derived from Epstein–Barr nuclear antigen 2 (EBNA2) of Epstein–Barr virus (Human herpesvirus 4). EBNA2 is a central transcriptional regulator expressed during early stages of EBV infection and plays a crucial role in the establishment of viral latency and the reprogramming of infected B cells.For a deeper understanding of the biological role of EBNA2 in early EBV infection and viral transcriptional control, explore the EBV Peptide Insights section by peptides&elephants. EBV EBNA2 280–290 corresponds to a linear T-cell epitope (IEDB ID 67007) located within the EBNA2 protein (UniProt ID: P12978). It has been experimentally studied for immune reactivity and evaluated in multiple functional T-cell assays. The epitope is presented in the context of HLA-DRB1*01:01, enabling recognition by CD4⁺ T cells. Experimental studies have demonstrated positive immune responses in several assay formats, including interferon-γ (IFNγ) release assays, T-cell proliferation assays, and cytotoxicity assays. These findings indicate that the peptide can effectively stimulate EBNA2-specific T-cell responses and is therefore suitable for applications in cellular immunology and EBV research. Because EBNA2 is a key driver of early transcriptional reprogramming in EBV-infected cells, peptides derived from this protein are valuable tools for studying virus-host interactions, T-cell immunity to EBV, and immune recognition of latency-associated antigens. Applications Stimulation of EBV-specific T cells ELISpot and FluoroSpot assays Intracellular cytokine staining (ICS) T-cell proliferation assays Cytotoxicity assays Epitope validation and immune monitoring in EBV research

From €109.20*

EBV EBNA3A 158-166 (HLA-B*08:01)

EBV EBNA3A 158-166 (HLA-B*08:01)

QAKWRLQTL is a linear peptidic epitope (epitope ID50298) studied as part of Epstein-Barr nuclear antigen 3 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*

EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01)

EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01)

The peptide EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) with the amino acid sequence IVTDFSVIK is a linear peptidic epitope (epitope ID 29466) studied as part of Epstein-Barr nuclear antigen 4 (UniProt:P03203) from Human herpesvirus 4 (Epstein Barr virus).EBV EBNA3B 416-424 (HLA-A*11:01; HLA-A*68:01) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

From €105.00*

EBV EBNA3C 281-290 (HLA-B*44:05)

EBV EBNA3C 281-290 (HLA-B*44:05)

EBNA3C-derived peptide of EENLLDFVRF covering 281-290 and B*44:05 molecule. The EBV EBNA3C 281-290 (HLA-B*44:05) peptide recognizes CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. EENLLDFVRF is a linear peptidic epitope (epitope ID11804) studied as part of Epstein-Barr nuclear antigen 6 from Human herpesvirus 4 (Epstein Barr virus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

From €105.00*